Literature DB >> 16985888

Sexual Function and alpha-Blockers.

Kevin T McVary.   

Abstract

Community-based studies and surveys have found an association between lower urinary tract symptoms (LUTS) and sexual dysfunction, in particular, erectile dysfunction (ED). The link between ED and LUTS has biologic plausibility. The following 4 theories have been used to explain how these disorders interrelate: 1) decreased or altered nitric oxide synthase/nitric oxide levels in the prostate and penile smooth muscle; 2) autonomic hyperactivity effects on LUTS, prostate growth, and ED; 3) increased Rho-kinase activation/endothelin activity; and 4) prostate and penile atherosclerosis. The relationship of LUTS and sexual dysfunction suggests that treatment of one condition may impact the other.

Entities:  

Year:  2005        PMID： 16985888      PMCID： PMC1477634     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  37 in total

1.  Sildenafil influences lower urinary tract symptoms.

Authors:  K Sairam; E Kulinskaya; T A McNicholas; G B Boustead; D C Hanbury
Journal:  BJU Int       Date:  2002-12       Impact factor: 5.588

2.  THE INCIDENCE OF BENIGN PROSTATIC HYPERPLASIA AND PROSTATIC CARCINOMA IN CIRRHOSIS OF THE LIVER.

Authors:  M C ROBSON
Journal:  J Urol       Date:  1964-10       Impact factor: 7.450

3.  The norepinephrine tissue concentration and neuropeptide Y immunoreactivity in genitourinary organs of the spontaneously hypertensive rat.

Authors:  Y C Tong; Y C Hung; S N Lin; J T Cheng
Journal:  J Auton Nerv Syst       Date:  1996-01-05

Review 4.  Age-related erectile and voiding dysfunction: the role of arterial insufficiency.

Authors:  T Tarcan; K M Azadzoi; M B Siroky; I Goldstein; R J Krane
Journal:  Br J Urol       Date:  1998-12

5.  Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.

Authors:  J M Buzelin; E Fonteyne; M Kontturi; W P Witjes; A Khan
Journal:  Br J Urol       Date:  1997-10

6.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

Authors:  John D McConnell; Claus G Roehrborn; Oliver M Bautista; Gerald L Andriole; Christopher M Dixon; John W Kusek; Herbert Lepor; Kevin T McVary; Leroy M Nyberg; Harry S Clarke; E David Crawford; Ananias Diokno; John P Foley; Harris E Foster; Stephen C Jacobs; Steven A Kaplan; Karl J Kreder; Michael M Lieber; M Scott Lucia; Gary J Miller; Mani Menon; Douglas F Milam; Joe W Ramsdell; Noah S Schenkman; Kevin M Slawin; Joseph A Smith
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

7.  Specificity of the American Urological Association voiding symptom index: comparison of unselected and selected samples of both sexes.

Authors:  T C Chai; W D Belville; E J McGuire; L Nyquist
Journal:  J Urol       Date:  1993-11       Impact factor: 7.450

8.  Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction.

Authors:  S A Kaplan; R B Reis; I J Kohn; R Shabsigh; A E Te
Journal:  Urology       Date:  1998-11       Impact factor: 2.649

9.  Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study.

Authors:  H A Feldman; I Goldstein; D G Hatzichristou; R J Krane; J B McKinlay
Journal:  J Urol       Date:  1994-01       Impact factor: 7.450

10.  The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study.

Authors:  R J Glynn; E W Campion; G R Bouchard; J E Silbert
Journal:  Am J Epidemiol       Date:  1985-01       Impact factor: 4.897
View more
  1 in total

Review 1.  The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Casey Lythgoe; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.